[On the effect of etofylline clofibrate on serum lipids and lipoproteins in patients with hyperlipoproteinemia of various degrees (author's transl)].
Efficacy and tolerance of 1-(theophyllin-7-yl)-ethyl-2-[2-(p-chlorophenoxy)-2-methylpropionate] (etofylline clofibrate, Duolip) was investigated in 54 out-patients, 18 of whom were of Fredrickson-Types IIa, IIb and IV, over a therapeutical period of 4 months, in comparison to initial and final placebo phases of 4 weeks each. In type IIa etofylline clofibrate shows a good effect on total cholesterol and on the cholesterol fractions, both with regard to the collective treated and to the low dosage of 750 mg/d etofylline clofibrate compared to the usual dosage of 1500 mg clofibrate. The activity of etofyllineclofibrate on type IIb is inconsistent. Decreases of total cholesterol, i.e., of VLDL cholesterol along with high decreases of triglycerides in VLDL and LDL are measurable, but not significant. In type IV total cholesterol is distinctly decreased, along with high decreases of VLDL cholesterol and particularly so of the relevant VLDL triglycerides. Subjective and objective tolerability of etofylline clofibrate was most favourable.
D002784:Cholesterol / Q000097:blood; D002994:Clofibrate / Q000031:analogs & derivatives* / Q000494:pharmacology; D006801:Humans; D006951:Hyperlipoproteinemias / Q000097:blood*; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood*; D014280:Triglycerides / Q000097:blood; D014527:Uric Acid / Q000097:blood
D000960:Hypolipidemic Agents; D008055:Lipids; D008074:Lipoproteins; D014280:Triglycerides; C028764:etofylline clofibrate; D014527:Uric Acid; D002784:Cholesterol; D002994:Clofibrate
Zur Wirkung von Etofyllinclofibrat auf Serumlipide und Lipoproteine bei Patienten mit verschiedenen Formen der Hyperlipoproteinämie.